ArticleMolecular neurobiology2025
Single-Nucleus RNA Sequencing of HDAC6 Inhibition in Resolving Doxorubicin-Induced Cognitive Impairment.
Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A systematic review of the neurobiological mechanisms of chemotherapy-induced deficits in executive functions.Brain, behavior, & immunity - health · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Breast cancer is the most common cancer worldwide, accounting for 12.5% of all new cases. Doxorubicin, an effective treatment for breast cancer, is associated with chemotherapy-induced cognitive impairment (CICI), which affects up to 82% of survivors. Currently, no interventions for CICI have been approved by the US Food and Drug Administration. Histone deacetylase 6 (HDAC6) inhibition has been shown to improve cognitive function in neurodegenerative disease models, and we previously reported that the HDAC6 inhibitor ACY-1083 restored CICI-related cognitive dysfunction. Here, we used behavioral testing and single-nucleus transcriptomic analysis of the hippocampi of female mice to evaluate the efficacy of ACY-1083 in reversing doxorubicin-induced CICI. Our results from cognitive testing (the novel object placement recognition task as a test for working memory; the puzzle box test as a measure executive functioning) suggest that HDAC6 inhibition successfully reverses CICI. We also identified specific cell populations and gene expression patterns in oligodendrocytes, astrocytes, microglia, and dentate gyrus granule cells from the hippocampus. Doxorubicin treatment upregulated genes related to neurodegeneration, impaired synaptic function, and oxidative stress. Treatment with ACY-1083 reversed some of the doxorubicin-induced changes in gene expression and created a unique transcriptomic phenotype in treated mice that was not present in untreated control mice. This unique phenotype was characterized by increased expression of genes related to neurodevelopment, neurite outgrowth, and mitochondrial function. Therefore, HDAC6 inhibition may not only reverse gene expression caused by doxorubicin treatment but may also induce a unique gene expression that contributes to cognitive function restoration via homeostatic mechanisms. Because HDAC6 inhibitors have been used successfully in clinical trials focusing on tolerability and safety, we suggest that HDAC6 inhibition may be a realistic and effective intervention for reversing CICI in cancer survivors.
Indexed as
Identifiers
40542954What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.